Cargando…

Characterization of the CD49f(+)/CD44(+)/CD24(−) single-cell derived stem cell population in basal-like DCIS cells

The molecular mechanisms responsible for the Ductal Carcinoma in Situ (DCIS)-Invasive Ductal Carcinoma (IDC) transition have yet to be elucidated. Due to the lack of molecularly targeted therapies, basal-like DCIS has a high risk of recurrence and progression to invasive and metastatic cancers. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Duru, Nadire, Gernapudi, Ramkishore, Lo, Pang-Kuo, Yao, Yuan, Wolfson, Benjamin, Zhang, Yongshu, Zhou, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216957/
https://www.ncbi.nlm.nih.gov/pubmed/27374087
http://dx.doi.org/10.18632/oncotarget.10203
Descripción
Sumario:The molecular mechanisms responsible for the Ductal Carcinoma in Situ (DCIS)-Invasive Ductal Carcinoma (IDC) transition have yet to be elucidated. Due to the lack of molecularly targeted therapies, basal-like DCIS has a high risk of recurrence and progression to invasive and metastatic cancers. In this study, by applying a novel single-cell clonogenic approach with the CD49f(+)/CD44(+)/CD24(−) surface markers, we characterized the aggressive clones that have enhanced self-renewal, migratory and invasive capacities derived from a human DCIS model cell line MCF10DCIS. The aggressive clones had elevated ALDH1 activity, lower global DNA methylation and increased expression of stem cell related genes, especially concurrent activation of SOX2/OCT4. In addition, we showed that the aggressive clones have increased expression of lincRNA-RoR and miR-10b compared to non-aggressive clones, which enhance their self-renewal and invasive abilities. Finally, we confirmed our in vitro results in vivo, demonstrating that aggressive clones were capable of forming tumors in nude mice, whereas non-aggressive clones were not. Our data suggest that lincRNA-RoR and miR10b could be used to distinguish aggressive clones from non-aggressive clones within the heterogeneous CD49f(+)/CD44(+)/CD24(−) DCIS population. Our findings also provide the foundation to develop new chemoprevention agents for DCIS-IDC transition.